Theleme Partners’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $409M | Sell |
8,048,245
-33,565
| -0.4% | -$1.57M | 27.24% | 1 |
|
|
2025
Q4 | $238M | Buy |
8,081,810
+13,000
| +0.2% | +$353K | 15.52% | 2 |
|
|
2025
Q3 | $208M | Buy |
8,068,810
+200,000
| +3% | +$5.58M | 13.32% | 3 |
|
|
2025
Q2 | $217M | Buy |
7,868,810
+626,420
| +9% | +$16.5M | 13.2% | 1 |
|
|
2025
Q1 | $205M | Sell |
7,242,390
-64,471
| -0.9% | -$2.29M | 16.14% | 1 |
|
|
2024
Q4 | $304M | Buy |
7,306,861
+80,000
| +1% | +$3.82M | 20.36% | 1 |
|
|
2024
Q3 | $483M | Hold |
7,226,861
| – | – | 27.61% | 1 |
|
|
2024
Q2 | $858M | Sell |
7,226,861
-94,936
| -1% | -$12M | 41.17% | 1 |
|
|
2024
Q1 | $780M | Sell |
7,321,797
-27,659
| -0.4% | -$2.79M | 39.54% | 1 |
|
|
2023
Q4 | $731M | Buy |
7,349,456
+451,844
| +7% | +$38M | 34.86% | 1 |
|
|
2023
Q3 | $712M | Buy |
6,897,612
+651,113
| +10% | +$72.6M | 35.78% | 1 |
|
|
2023
Q2 | $759M | Buy |
6,246,499
+134,065
| +2% | +$17.9M | 34.35% | 1 |
|
|
2023
Q1 | $939M | Buy |
6,112,434
+253,576
| +4% | +$41.8M | 40.37% | 1 |
|
|
2022
Q4 | $1.05B | Sell |
5,858,858
-145,548
| -2% | -$23.8M | 39.69% | 1 |
|
|
2022
Q3 | $710M | Sell |
6,004,406
-350,000
| -6% | -$53.1M | 34.63% | 1 |
|
|
2022
Q2 | $908M | Buy |
6,354,406
+17,466
| +0.3% | +$2.5M | 36.37% | 1 |
|
|
2022
Q1 | $1.09B | Buy |
6,336,940
+1,314,766
| +26% | +$221M | 34.87% | 1 |
|
|
2021
Q4 | $1.28B | Buy |
5,022,174
+1,065,100
| +27% | +$311M | 21.32% | 2 |
|
|
2021
Q3 | $1.52B | Sell |
3,957,074
-2,114,982
| -35% | -$780M | 43.47% | 1 |
|
|
2021
Q2 | $1.43B | Sell |
6,072,056
-230,000
| -4% | -$41.1M | 41.66% | 1 |
|
|
2021
Q1 | $825M | Buy |
6,302,056
+958,358
| +18% | +$139M | 27.62% | 1 |
|
|
2020
Q4 | $558M | Sell |
5,343,698
-2,309,280
| -30% | -$234M | 18.33% | 2 |
|
|
2020
Q3 | $541M | Sell |
7,652,978
-893,941
| -10% | -$62.3M | 24.88% | 1 |
|
|
2020
Q2 | $549M | Sell |
8,546,919
-384,000
| -4% | -$21M | 25.9% | 1 |
|
|
2020
Q1 | $267M | Buy |
8,930,919
+2,490,645
| +39% | +$57.3M | 19.24% | 2 |
|
|
2019
Q4 | $126M | Buy |
6,440,274
+827,829
| +15% | +$14.7M | 7.1% | 5 |
|
|
2019
Q3 | $89.3M | Buy |
5,612,445
+1,757,647
| +46% | +$26M | 4.13% | 9 |
|
|
2019
Q2 | $56.4M | Buy |
3,854,798
+2,222,285
| +136% | +$47.7M | 2.74% | 10 |
|
|
2019
Q1 | $33.2M | Buy |
1,632,513
+502,513
| +44% | +$9.33M | 1.98% | 8 |
|
|
2018
Q4 | $17.3M | Buy |
+1,130,000
| New | +$18.6M | 0.87% | 10 |
|
Other funds holding MRNA
VCM
VPM
Theleme Partners's MRNA Position: Q1 2026 in Review
Theleme Partners reduced its Moderna (MRNA) stake by 0.42% in Q1 2026, selling an estimated $1.57M and leaving 8,048,245 shares worth $409M. The position accounts for 27.24% of the portfolio, ranked #1.
Theleme Partners first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.52B in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.
- Theleme Partners held 8,048,245 shares of Moderna worth $409M as of Q1 2026.
- Theleme Partners sold 33,565 Moderna shares in Q1 2026, an estimated $1.57M.
- Moderna made up 27.24% of Theleme Partners's portfolio in Q1 2026, its #1 holding.
- Theleme Partners first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
- Theleme Partners's Moderna position peaked at $1.52B in Q3 2021.
- 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.
Based on Theleme Partners's 13F filing for Q1 2026, filed 15 May 2026.